Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The substantial decrease in royalties, the decline in overseas pharmaceuticals and lower unit prices for domestic pharmaceuticals contributed to the revenue decline. Meanwhile, the LAL business and contract manufacturing of pharmaceutical active ingredients and pharmaceuticals generated higher revenue. Selling, general and administrative expenses declined due to lower research and development expenses and other factors. Gains on the sale of investment securities, foreign exchange gains resulting from the weaker yen and a review of the amount of deferred tax assets recognized affected profit.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥36,645 million (YoY -6.9%) |
| Operating profit | ¥-660 million |
| Ordinary income | ¥1,679 million (YoY -13.1%) |
| Profit attributable to owners of the parent | ¥1,473 million (YoY +21.3%) |
| Net income per share | ¥26.99 |
| Operating Margin | Current fiscal year -1.8 % / Previous period 3.4 % |
| Equity ratio | End of the current fiscal period 87.2 % / End of previous period 87.3 % |
| Total assets | ¥86,344 million |
| Net assets | ¥75,299 million |
| Cash flows from operating activities | ¥-1,347 million |
| Cash flows from investing activities | ¥-3,508 million |
| Cash flows from financing activities | ¥-1,677 million |
| Cash and cash equivalents at end of period | ¥12,059 million |
| Full-year earnings forecast | Net Sales ¥41,850 million (YoY +14.2%) / Operating profit ¥2,050 million / Ordinary income ¥4,200 million (YoY +150.0%) / Profit attributable to owners of the parent ¥2,250 million (YoY +52.7%) |
| Annual Dividend Forecast | ¥30 per share → ¥30 per share（0.0%） |
| Payout ratio | Fiscal year ending March 2026 111.2 % / Forecast for the fiscal year ending March 2027 72.8 % |
| Shareholder Return Policy | The basic annual dividend is ¥26 per share. The Company will consider increasing the dividend in light of earnings trends, financial condition and other factors. The Company will also consider acquiring treasury shares as appropriate, taking into account the total payout ratio. |
| Segment revenue | Pharmaceuticals ¥24,493 million (YoY -11.0%), LAL ¥12,152 million (YoY +2.5%) |
| Segment profit | Pharmaceuticals ¥-1,635 million, LAL ¥975 million |
| Regional sales | Domestic pharmaceuticals ¥11,868 million (YoY -0.4%), Overseas pharmaceuticals ¥9,369 million (YoY -4.4%) |
| Depreciation and amortization | ¥1,984 million |
| Impairment loss | ¥169 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥169 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Analysts and institutional investors |
| Issued Shares at Period-End | 56,814,093 |
| Treasury Shares at Period-End | 2,211,301 |
| Factors Behind Changes in Business Performance | The substantial decrease in royalties, the decline in overseas pharmaceuticals and lower unit prices for domestic pharmaceuticals contributed to the revenue decline. Meanwhile, the LAL business and contract manufacturing of pharmaceutical active ingredients and pharmaceuticals generated higher revenue. Selling, general and administrative expenses declined due to lower research and development expenses and other factors. Gains on the sale of investment securities, foreign exchange gains resulting from the weaker yen and a review of the amount of deferred tax assets recognized affected profit. |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined due to a substantial decrease in royalties and a decline in overseas pharmaceuticals. Operating profit turned into a loss as a result of the revenue decline, while ordinary profit was affected by gains on the sale of investment securities and other factors, and net profit attributable to owners of the parent was affected by a review of the amount of deferred tax assets recognized.